4. Have previously received no more than two types of systemic anti-tumor therapy, including long-acting somatostatin analogs (SSAs), interferon,peptide receptor radionuclide therapy, themammaliantargetofrapamycin (mTOR) inhibitors or chemotherapy; patients who are unable or unwilling to receive such treatments are also eligible;